Ph positive acute lymphoblastic leukemia in adults: molecular and clinical studies
G Specchia, D Mininni, A Guerrasio… - Leukemia & …, 1995 - Taylor & Francis
G Specchia, D Mininni, A Guerrasio, G Palumbo, D Pastore, V Liso
Leukemia & lymphoma, 1995•Taylor & FrancisFifty-six patients with ALL were investigated for ber involvement by PCR. Breakpoints were
found in 15 patients (26.8%). There were no differences in clinical and hematologic features
or the percentages of complete response (CR) between the Ph+ and Ph-cases. The duration
of CR was 6 and 8 months, respectively. In 7/9 Ph1 relapsed ALL we observed increased
expression of myeloid markers and 2/9 showed a switch of cytotype (Ly→ My). In none of the
13 Ph-relapsed ALL. patients did we observe these findings. 7/15 of Ph+ cases expressed …
found in 15 patients (26.8%). There were no differences in clinical and hematologic features
or the percentages of complete response (CR) between the Ph+ and Ph-cases. The duration
of CR was 6 and 8 months, respectively. In 7/9 Ph1 relapsed ALL we observed increased
expression of myeloid markers and 2/9 showed a switch of cytotype (Ly→ My). In none of the
13 Ph-relapsed ALL. patients did we observe these findings. 7/15 of Ph+ cases expressed …
Fifty-six patients with ALL were investigated for ber involvement by PCR. Breakpoints were found in 15 patients (26.8%). There were no differences in clinical and hematologic features or the percentages of complete response (CR) between the Ph+ and Ph- cases. The duration of CR was 6 and 8 months, respectively. In 7/9 Ph1 relapsed ALL we observed increased expression of myeloid markers and 2/9 showed a switch of cytotype (Ly → My). In none of the 13 Ph- relapsed ALL. patients did we observe these findings. 7/15 of Ph+ cases expressed P190 and mRNA ela2 and 8/15 patients showed P210, with mRNA b3a2 in 5 and b2a2 in 3, respectively. The percentage of CR was 57% in the P190+ and 87% in the P210+ group. Investigation of more Ph1+ALL cases treated with a uniform protocol should be performed in the future in order to determine whether any such biological and clinical differences exist.
Taylor & Francis Online